Total 2 articles
Insilico Medicine Hong Kong IPO 2025 debuts with a 46% stock jump, raising $300m. The firm eyes expansion into the LLM market to drive future growth.
Insilico Medicine goes public in Hong Kong, unveiling its 'digital Einstein' AI to tackle the 90% failure rate in the 'molecular casino' of drug discovery.
Advertise with Us